Estrogenic activities of isoflavones and flavones and their structure-activity relationships

Planta Medica

Volumn 74, Issue 1, 2008, Pages 25-32

  Sun, Young Choi ^a   Tae, Youl Ha ^a   Ji, Yun Ahn ^a   Sung, Ran Kim ^a   Kyung, Sun Kang ^b   In, Kyeong Hwang ^b   Kim, Suna ^a  

^a Korea Food Research Institute   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

E screen assay; ER binding assay; Flavones; Isoflavones; QSAR; Yeast transactivation assay

Indexed keywords

4',6,7 TRIHYDROXYISOFLAVONE; 7,4' DIHYDROXYFLAVONE; APIGENIN; BIOCHANIN A; CHRYSIN; COUMESTROL; DAIDZEIN; EQUOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FLAVONE DERIVATIVE; FORMONONETIN; GENISTEIN; GLYCITEIN; ISOFLAVONE DERIVATIVE; ISOLIQUIRITIGENIN; KAEMPFEROL; QUERCETIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; ESTROGEN ACTIVITY; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RECEPTOR BINDING; YEAST;

BIOLOGICAL ASSAY; FLAVONES; HUMANS; ISOFLAVONES; PHYTOESTROGENS; PHYTOTHERAPY; PLANTS, MEDICINAL; SACCHAROMYCES CEREVISIAE; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION, GENETIC;

EID: 39149092009     PISSN: 00320943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-993760     Document Type: Article

References (28)

1. Rosenberg RS, Jenkins DJA, Diamandis EP. Steroid hormone activity of flavonoids and related compounds. Breast Cancer Res Treat 2000; 62: 35-49
2. Cos P, Bruyne TD, Apers S, Berghe DV, Pieters L, Vlietinck AJ. Phytoestrogens: recent developments. Planta Med 2003; 69: 589-99
3. Collins-Burow BM, Burow ME, Duong BN, McLachlan JA. Estrogenic and antiestrogenic activities of flavonoid phytochemicals through estrogen receptor binding-dependent and -independent mechanisms. Nutr Cancer 2000; 38: 229-44
4. Green S, Walter P, Greene G, Krust A, Goffin C, Jensen E et al. Cloning of the human oestrogen receptor cDNA. J Steroid Biochem 1986; 24: 77-83
5. Levenson AS, Jordan VC. Selective oestrogen receptor modulation: molecular pharmacology for the millennium. Eur J Cancer 1999; 35: 1628-39
6. Pike A, Brzozowski A, Hubbard R, Bonn T, Thorsell A-G, Engström O et al. Structure of the ligand-binding domain of estrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J 1999; 18: 4608-18
7. Miksicek RJ. Interaction of naturally occurring nonsteroidal estrogens with expressed recombinant human estrogen receptor. J Steroid Biochem Mol Biol 1994; 49: 153-60
8. Routledge EJ, White R, Parker MG, Sumpter JP. Differential effects of xenoestrogens on coactivator recruitment by estrogen receptor(ER)α and ERβ. J Biol Chem 2000; 275: 35986-93
9. Jordan VC, Mittal S, Gosden B, Koch R, Lieberman ME. Structure-activity relationships of estrogens. Environ Health Perspect 1985; 61: 97-110
10. Soto AM, Sonnenschein C, Chung KL, Fernandez MF, Olea N, Serrano FO. The E-SCREEN assay as a tool to identify estrogens: an update on estrogenic environmental pollutants. Environ Health Perspect 1995; 103: 113-22
11. Routledge EJ, Sumpter JP. Estrogenic activity of surfactants and some of their degradation products assessed using a recombinant yeast screen. Environ Toxicol Chem 1996; 15: 241-8
12. Pons M, Gagne D, Nicolas JC, Mehtali R. A new cellular model of response to estrogens: a bioluminescent test to characterize (anti)estrogen molecules. Biotechniques 1990; 9: 450-9
13. Legler J, van den Brink CE, Brouwer A, Murk AJ, van der Saag PT, Vethaak AD et al. Development of a stably transfected estrogen receptor-mediated luciferase reporter gene assay in the human T47D breast cancer cell line. Toxicol Sci 1999; 48: 55-66
14. Zacharewski T. In vitro bioassays for estrogenic substances. Environ Sci Technol 1997; 31: 613-23
15. Zacharewski T. Identification and assessment of endocrine disruptors: limitations of in vivo and in vitro assays. Environ Health Perspect 1998; 106: 577-82
16. Jacobs MN. In silico tools to aid risk assessment of endocrine disrupting chemicals. Toxicology 2004; 205: 43-53
17. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63
18. Ohno Y, Azuma Y, Date K, Nakano S, Kobayashi T, Nagao Y et al. Evaluation of styrene oligomers eluted from polystyrene for estrogenicity in estrogen receptor binding assay, reporter gene assay, and uterotrophic assay. Food Chem Toxicol 2003; 41: 131-41
19. Roberge M, Hakk H, Larsen G. Atrazine is a competitive inhibitor of phosphodiesterase but does not affect the estrogen receptor. Toxicol Lett 2004; 154: 61-8
20. lck protein tyrosine kinase: A classical/quantum chemical approach. Quant Structure-Activity Relat 1998; 17: 7-13
21. Tong W, Perkins R. QSAR models for binding of estrogenic compounds to estrogen receptor α and β subtypes. Endocrinology 1997; 138: 4022-5
22. Maggiolini M, Bonofiglio D, Marsico S, Panno ML, Cenni B, Picard D et al. Estrogen receptor α mediates the proliferative but not cytotoxic dose-dependent effects of two major phytoestrogens on human breast cancer cells. Mol Pharmacol 2001; 60: 595-602
23. Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann MP et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY 294002, quercetin, myricetin, and staurosporine. Mol Cell 2000; 6: 909-19
24. Fang H, Tong W, Shi LM, Blair R, Perkins R, Branham W et al. Structure-activity relationships for a large diverse set of natural, synthetic, and environmental estrogens. Chem Res Toxicol 2001; 14: 280-94
25. Peterson TG, Coward L, Kirk M, Falany CN, Barnes S. The role of metabolism in mammary epithelial cell growth inhibition by the isoflavones genistein and biochanin A. Carcinogenesis 1996; 17: 1861-9
26. Wenzel DG, Rosenberg P. Estrogenic activity of some flavonoids. J Am Pharm Assoc 1956; 45: 367-9
27. Lerner LJ, Turkheimer AR, Borman A. Phloretin, a weak estrogen and estrogen antagonist. Proc Soc Exp Biol Med 1963; 114: 115-7
28. Miksicek RJ. Estrogenic flavonoids: structural requirements for biological activity. Proc Soc Exp Biol Med 1995; 208: 44-50